<DOC>
	<DOC>NCT02232906</DOC>
	<brief_summary>Investigation whether a switch from oral iron to intravenous ferric carboxymaltose can reduce dose requirements of erythropoiesis-stimulating agents (ESA) and improve Hb levels and iron status in adult patients with non-dialysis-dependent CKD who were on a stable ESA/oral iron schedule for 6 months prior to enrolment.</brief_summary>
	<brief_title>Switch From Oral Iron to Intravenous Ferric Carboxymaltose in Non-dialysis Chronic Kidney Disease (CKD)</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>&gt;18 years of age Creatinine clearance ≤40 mL/min Hemoglobin 110120 g/L Serum ferritin &lt;100 µg/L or transferrin saturation &lt;20% Monthly treatment with ESA and oral iron for at least six months before enrolment Other obvious cause of acute or chronic anemia than iron deficiency Expectation to require hemodialysis within the next six months Short life expectancy (&lt;1 year) Pregnancy Decompensated heart failure History of allergic reactions to iron preparations and/or anaphylaxis from any cause Requirement of blood transfusions Chronic decompensated mental disorder or dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>non-dialysis-dependent</keyword>
	<keyword>ND-CKD</keyword>
	<keyword>Erythropoiesis-stimulating agent</keyword>
	<keyword>Ferric carboxymaltose</keyword>
	<keyword>Iron</keyword>
</DOC>